Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Mitogen Activated Protein Kinase 14 Therapeutics Report 2016: Pipeline Review of 10 Companies & 13 Molecules - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2016" report to their offering.

Mitogen Activated Protein Kinase 14 pipeline Target constitutes close to 13 molecules.

Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2016, outlays comprehensive information on the Mitogen Activated Protein Kinase 14 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Mitogen Activated Protein Kinase 14 Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Mitogen Activated Protein Kinase 14 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Mitogen Activated Protein Kinase 14 Overview
  3. Therapeutics Development
  4. Pipeline Products for Mitogen Activated Protein Kinase 14 - Overview
  5. Pipeline Products for Mitogen Activated Protein Kinase 14 - Comparative Analysis
  6. Mitogen Activated Protein Kinase 14 - Therapeutics under Development by Companies
  7. Mitogen Activated Protein Kinase 14 - Therapeutics under Investigation by Universities/Institutes
  8. Mitogen Activated Protein Kinase 14 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Mitogen Activated Protein Kinase 14 - Products under Development by Companies
  13. Mitogen Activated Protein Kinase 14 - Products under Investigation by Universities/Institutes
  14. Mitogen Activated Protein Kinase 14 - Companies Involved in Therapeutics Development
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Chroma Therapeutics Limited
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Synovo GmbH
  • Toray Industries, Inc.
  • Zocere, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/phstbt/mitogen_activated

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006419/en/

Business Wire
www.businesswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.